Cancer Pain Management — Part 5: Special Populations, Non-Pharmacological Approaches, Palliative Sedation, and Survivorship Pain
Pain management in elderly, pediatric, renal/hepatic impairment, and substance use disorder populations; non-pharmacological interventions; palliative sedation; and survivorship chronic pain strategies.
Special Populations
Elderly Patients
Cancer is disproportionately a disease of older adults, and pain management in the elderly requires specific adjustments to account for age-related pharmacokinetic and pharmacodynamic changes, comorbidities, polypharmacy, and altered pain perception and reporting.1
Pharmacokinetic Considerations
| Parameter | Age-Related Change | Clinical Implication |
|---|---|---|
| Body composition | Increased fat-to-lean ratio; decreased total body water | Increased volume of distribution for lipophilic drugs (fentanyl, methadone); higher peak concentrations of hydrophilic drugs (morphine) |
| Hepatic metabolism | Decreased hepatic blood flow (25–40% reduction); reduced Phase I metabolism (CYP450); Phase II (glucuronidation) relatively preserved | Slower clearance of drugs requiring oxidative metabolism (methadone, fentanyl); morphine clearance (glucuronidation) less affected |
| Renal function | Age-related decline in GFR (even without elevated creatinine) | Accumulation of renally excreted drugs and active metabolites (morphine-6-glucuronide, codeine metabolites); use serum creatinine-based GFR estimation cautiously — may overestimate function in elderly with low muscle mass |
| Plasma proteins | Decreased serum albumin (in cachectic or malnourished patients) | Higher free fraction of protein-bound drugs; may enhance effect and toxicity |
Opioid Prescribing in the Elderly
| Principle | Recommendation |
|---|---|
| Starting doses | Start at 25–50% of standard adult starting doses |
| Titration | “Start low, go slow” — titrate in smaller increments (25% increases) over longer intervals |
| Drug selection | Hydromorphone or oxycodone may be preferred over morphine (less active metabolite accumulation); fentanyl transdermal is an option for stable pain if patient has adequate subcutaneous tissue; avoid meperidine (normeperidine accumulation causing seizures) |
| Methadone | Extra caution required; longer QTc at baseline is more common in elderly; slower titration (increases no more frequently than every 7 days) |
| Codeine | Generally avoided; unpredictable metabolism; constipation is poorly tolerated |
| Tramadol | Use with caution; lower seizure threshold is a concern, especially with concomitant medications |
| Monitoring | More frequent assessment for sedation, confusion, falls, constipation |
| Adjuvants | Gabapentin: start at 100 mg at bedtime; very slow titration; TCAs: avoid amitriptyline (anticholinergic burden); nortriptyline or desipramine at lowest doses if needed |
| NSAIDs | Higher risk of GI bleeding, renal impairment, cardiovascular events, and drug interactions in elderly; use lowest dose for shortest duration; always with PPI; COX-2 selective agents may be preferred for GI safety but carry cardiovascular risk |
| Acetaminophen | Limit to 2000–3000 mg/day in elderly; reduced hepatic reserve |
Assessment Considerations
- Use validated tools appropriate for cognitive status; Wong-Baker FACES or NRS for cognitively intact elderly; FLACC or PAINAD (Pain Assessment in Advanced Dementia) for patients with dementia
- PAINAD scale: 5-item behavioral observation tool (breathing, negative vocalization, facial expression, body language, consolability) scored 0–10; designed specifically for patients with advanced dementia who cannot self-report
Pediatric Considerations
While this guideline focuses on adult cancer pain, many principles are shared, and clinicians caring for adolescents and young adults should be aware of key pediatric considerations. Dedicated pediatric oncology pain guidelines should be consulted for patients under 18 years.2
Age-Appropriate Pain Assessment
| Age Group | Recommended Tools |
|---|---|
| Neonates and infants (0–1 year) | FLACC; NIPS (Neonatal Infant Pain Scale) |
| Toddlers (1–3 years) | FLACC; behavioral observation |
| Preschool (3–6 years) | Wong-Baker FACES (from age 3); FLACC as adjunct |
| School-age (6–12 years) | Wong-Baker FACES; NRS (from approximately age 8) |
| Adolescents (12–18 years) | NRS; VAS; BPI (as in adults) |
Opioid Dosing in Pediatrics
| Opioid | Route | Weight-Based Starting Dose | Notes |
|---|---|---|---|
| Morphine | IV | 0.05–0.1 mg/kg every 2–4 hours | Standard first-line; titrate to effect |
| Morphine | Oral | 0.15–0.3 mg/kg every 4 hours | Available as oral solution |
| Oxycodone | Oral | 0.05–0.15 mg/kg every 4–6 hours | Alternative to morphine |
| Hydromorphone | IV | 0.015 mg/kg every 3–4 hours | For patients with morphine intolerance |
| Hydromorphone | Oral | 0.03–0.08 mg/kg every 3–4 hours | Available as oral liquid |
| Fentanyl | IV | 0.5–1 mcg/kg every 1–2 hours | Short-acting; useful for procedures |
| Fentanyl | Transdermal | Calculated from current opioid requirement | Only for opioid-tolerant children over age 2 with stable analgesic requirements |
Key pediatric principle: Weight-based dosing; no maximum dose for cancer pain — titrate to effect with appropriate monitoring.
Renal Impairment
Renal impairment significantly affects the safety profile of several opioids due to accumulation of active or toxic metabolites. Opioid selection and dose adjustment in renal impairment are critical to prevent toxicity.3
Opioid Selection by Renal Function
| GFR (mL/min) | Preferred Opioids | Use with Caution | Avoid |
|---|---|---|---|
| Greater than 60 | Any opioid appropriate | — | Meperidine (any GFR) |
| 30–60 | Fentanyl, hydromorphone, methadone, oxycodone (reduced dose) | Morphine (reduce dose by 25–50%, extend interval); tramadol (reduce dose) | Meperidine; codeine (unreliable metabolism) |
| 15–30 | Fentanyl, methadone | Hydromorphone (reduce dose significantly); oxycodone (reduce dose significantly) | Morphine; codeine; meperidine; tramadol ER |
| Less than 15 or dialysis | Fentanyl (not dialyzed, but dosing unchanged); methadone (not dialyzed; no dose adjustment needed) | Hydromorphone (reduce dose, monitor closely for H3G accumulation at very low GFR) | Morphine; codeine; meperidine; tramadol |
Fentanyl is often considered the safest opioid in severe renal impairment because it has no active metabolites and is not significantly removed by dialysis. However, it is available primarily in transdermal and parenteral formulations, which limits flexibility for dose titration.
Methadone is also relatively safe in renal impairment (hepatic metabolism, no active metabolites, not dialyzed), but requires expertise in management and QTc monitoring.
Hepatic Impairment
| Principle | Recommendation |
|---|---|
| General approach | Reduce dose and extend dosing interval for all opioids; start at 50% of normal starting dose in moderate impairment; 25% in severe impairment |
| Morphine | Reduced clearance; start at 50% of normal dose; monitor closely; bioavailability increases due to reduced first-pass metabolism |
| Oxycodone | Reduced clearance; start at one-third to one-half of normal dose; significant first-pass effect means oral bioavailability increases in hepatic impairment |
| Hydromorphone | Glucuronidation may be relatively preserved in mild-moderate impairment; reduce dose in severe impairment |
| Fentanyl | Reduced clearance in hepatic impairment; reduce dose; transdermal absorption kinetics may be altered (not well-studied in severe hepatic impairment) |
| Methadone | Hepatic metabolism; reduced clearance; start at lower dose; longer titration intervals; monitor closely |
| Acetaminophen | Reduce maximum to 2000 mg/day; avoid in severe hepatic impairment (Child-Pugh C) |
| NSAIDs | Avoid in significant hepatic impairment; increased GI bleeding risk (portal hypertension, coagulopathy); renal vasoconstriction risk in hepatorenal physiology |
| Adjuvants | Duloxetine: avoid in severe hepatic impairment; gabapentin/pregabalin: no hepatic dose adjustment needed (renally cleared) |
Patients with Substance Use Disorder History
Cancer pain management in patients with a current or past substance use disorder (SUD) is among the most challenging clinical scenarios. These patients have the same right to effective pain management as any other patient, and their pain should not be undertreated due to addiction-related stigma. However, modified monitoring and prescribing strategies are needed to manage both pain and SUD risk.4
General Principles
- Pain should be treated effectively. Undertreatment causes suffering and may paradoxically drive aberrant drug-seeking behavior.
- Addiction risk does not contraindicate opioid therapy when opioids are indicated for cancer pain, but it does require enhanced structure and monitoring.
- Multidisciplinary approach: Collaborate with addiction medicine, psychiatry, palliative care, and social work.
- Distinguish physical dependence and tolerance from addiction. Physical dependence (withdrawal with abrupt cessation) and tolerance (need for higher doses over time) are expected physiological phenomena with chronic opioid use and are NOT diagnostic of addiction.
Structured Opioid Prescribing for Patients with SUD History
| Strategy | Implementation |
|---|---|
| Single prescriber | Designate one clinician to prescribe all opioids |
| Single pharmacy | Use one pharmacy for all opioid dispensing |
| Frequent visits | More frequent follow-up (weekly to biweekly during initial treatment) |
| Smaller prescription quantities | Prescribe 1–2 week supplies rather than 4-week supplies |
| Tamper-resistant formulations | Consider abuse-deterrent opioid formulations when available and appropriate |
| Urine drug screening | Baseline and periodic urine drug screens to confirm adherence and detect undisclosed substances; interpret results in clinical context (immunoassay may miss synthetic opioids; confirm with LC-MS/MS if needed) |
| Prescription drug monitoring program (PDMP) | Check the state PDMP before each opioid prescription |
| Avoid specific agents | Avoid meperidine (abuse potential, toxic metabolite); use caution with transmucosal fentanyl (rapid onset may be reinforcing); avoid benzodiazepines if possible |
| Treatment agreement | Consider a structured treatment agreement documenting expectations (not as a punitive measure but as a communication tool) |
| Naloxone co-prescribing | Prescribe naloxone rescue kit for home use |
| Address the SUD | Concurrent addiction treatment; consider buprenorphine-based therapy for patients with co-occurring opioid use disorder (see below) |
Buprenorphine in Cancer Pain with Opioid Use Disorder
Buprenorphine is a partial mu-opioid agonist and kappa-opioid antagonist with a ceiling effect for respiratory depression but no practical ceiling for analgesia at typical clinical doses. It offers the unique advantage of simultaneously treating opioid use disorder and providing analgesia.
| Formulation | Dose for Pain | Notes |
|---|---|---|
| Buprenorphine transdermal (low-dose pain formulation) | 5–20 mcg/hr, changed every 7 days | For chronic pain; does NOT treat opioid use disorder at these doses |
| Buprenorphine buccal film | 75–900 mcg every 12 hours | For chronic pain; various strengths available |
| Buprenorphine sublingual/buccal (with or without naloxone) | 8–24 mg/day sublingual (for OUD); analgesic effect provided by TID or QID dosing of the total daily dose | Higher doses for OUD maintenance; may provide adequate analgesia; can be supplemented with non-opioid analgesics and adjuvants; combination with full mu-agonist opioids is complex and should involve experienced clinicians |
Non-Pharmacological Approaches
Non-pharmacological interventions are an integral component of comprehensive cancer pain management and should be offered to all patients as part of a multimodal strategy. They complement but do not replace pharmacological therapy for moderate-to-severe cancer pain.5
Psychological Interventions
Cognitive Behavioral Therapy (CBT)
| Parameter | Detail |
|---|---|
| Mechanism | Addresses maladaptive thoughts (catastrophizing, helplessness), emotions, and behaviors that amplify pain perception and suffering; teaches coping strategies, relaxation, and activity pacing |
| Evidence | Moderate-quality evidence for reduction of cancer pain intensity and pain-related distress; recommended by multiple guidelines as part of comprehensive pain management |
| Format | Typically 6–12 sessions; can be delivered individually or in groups; increasingly available via telehealth |
| Components | Pain education, cognitive restructuring, relaxation training (progressive muscle relaxation, diaphragmatic breathing), guided imagery, activity pacing, goal setting, problem solving |
| Indications | All cancer patients with persistent pain; especially those with comorbid anxiety, depression, or catastrophizing; survivors with chronic pain |
Mindfulness-Based Stress Reduction (MBSR)
- Structured 8-week program combining mindfulness meditation, body awareness, and gentle movement
- Moderate evidence for improvement in pain severity, pain interference, and quality of life in cancer patients
- Mechanism: alters cognitive and emotional processing of pain; reduces stress-related amplification
Acceptance and Commitment Therapy (ACT)
- Third-wave behavioral therapy focusing on psychological flexibility, acceptance of pain experience, and engagement in values-based activity despite pain
- Growing evidence base in chronic pain; limited but promising evidence specifically in cancer pain
Hypnosis
- Clinical hypnosis (self-hypnosis techniques taught by a trained professional) has evidence for reduction of procedural pain and chronic cancer pain
- May be particularly useful for procedural anxiety and pain (bone marrow biopsies, lumbar punctures)
Physical and Rehabilitation Therapies
| Modality | Mechanism | Evidence in Cancer Pain | Notes |
|---|---|---|---|
| Physical therapy / exercise | Improves function, reduces deconditioning, modulates pain through central mechanisms; reduces fatigue | Moderate evidence for improvement in pain, function, and quality of life across the cancer continuum | Individualized program; supervised initially; aerobic, strengthening, flexibility, and balance components; modify for bone metastases (avoid high-impact loading) |
| Occupational therapy | Adaptive strategies, assistive devices, energy conservation | Improves function and independence with pain-limited activities | Particularly useful for hand and upper extremity CIPN |
| Transcutaneous electrical nerve stimulation (TENS) | Gate control theory; modulation of peripheral nerve signaling | Limited evidence in cancer pain; may provide modest benefit for some patients | Low risk; patient-controlled; may be tried as adjunct for localized pain |
| Heat therapy | Increases local blood flow, muscle relaxation, reduces stiffness | Widely used for musculoskeletal pain; avoid over tumor sites or radiation fields | Moist heat preferred; avoid burns in areas of sensory loss |
| Cold therapy | Vasoconstriction, reduced local inflammation, nerve conduction slowing | Useful for acute inflammatory pain, post-procedural pain | Avoid in areas of vascular compromise or Raynaud phenomenon |
| Massage therapy | Relaxation, reduced muscle tension, improved circulation, psychosocial benefit | Moderate evidence for short-term reduction in pain and anxiety in cancer patients; effects may be short-lived | Modify pressure for thrombocytopenia, bone metastases, skin fragility; avoid deep pressure over tumor sites; lymphedema considerations |
| Lymphedema therapy | Manual lymphatic drainage, compression therapy | Reduces lymphedema-associated pain and heaviness | Trained lymphedema therapist required |
Integrative Medicine Approaches
Acupuncture
| Parameter | Detail |
|---|---|
| Evidence for cancer pain | Growing body of evidence; multiple randomized trials and systematic reviews suggest benefit for various cancer pain types including aromatase inhibitor-induced arthralgia, post-surgical pain, and general cancer pain |
| Evidence for CIPN | Emerging evidence; small randomized trials suggest improvement in CIPN symptoms; several guidelines recognize it as a reasonable option |
| Mechanism | Neuromodulatory effects including endogenous opioid release, anti-inflammatory cytokine modulation, and central nervous system pathway modulation |
| Safety | Very low risk when performed by qualified practitioners; avoid needling into areas of lymphedema, neutropenic patients (infection risk), severe thrombocytopenia (bleeding risk — typically avoid if platelets below 20,000–50,000/mcL), or near tumor sites |
| Recommendation | May be offered as an adjunct to standard pain management; particularly for musculoskeletal pain, CIPN, and aromatase inhibitor arthralgia |
Music Therapy
- Formal music therapy (conducted by a credentialed music therapist) and music-based interventions have evidence for reduction of pain, anxiety, and mood disturbance in cancer patients
- Low risk; widely applicable; can be incorporated into inpatient, outpatient, and hospice settings
Yoga
- Gentle, cancer-adapted yoga programs have evidence for reduction of pain, fatigue, and improvement in quality of life
- Modified programs avoiding excessive strain, appropriate for patients with bone metastases or physical limitations
- Includes components of physical movement, breathing techniques, and meditation
Palliative Sedation
Definition and Ethical Framework
Palliative sedation is the monitored use of medications to induce a state of reduced or absent awareness in order to relieve refractory suffering at the end of life. It is considered an intervention of last resort when all other reasonable therapeutic options have been exhausted or are inappropriate for the clinical situation.6
Refractory symptom: A symptom for which all available treatments have failed, or for which available treatments are assessed as unlikely to provide adequate relief within a tolerable time frame and with an acceptable risk-benefit ratio. Determination of refractoriness requires input from palliative care specialists and, ideally, multidisciplinary review.
Ethical distinction: Palliative sedation is ethically distinct from euthanasia. The intent of palliative sedation is to relieve suffering through reduced consciousness; the intent is NOT to hasten death. Multiple professional ethics bodies, including those of major medical associations and the ethics committees of professional oncology, palliative care, and hospice organizations, affirm the ethical permissibility of palliative sedation for refractory symptoms when properly indicated and conducted.
Indications
- Refractory pain (after optimization of all appropriate pharmacological, interventional, and non-pharmacological approaches)
- Refractory delirium (agitated delirium not responsive to standard management)
- Refractory dyspnea
- Refractory seizures
- Other intolerable refractory symptoms (e.g., massive hemorrhage, psychological/existential suffering — controversial)
Prerequisites
- The symptom must be determined to be truly refractory by clinicians experienced in symptom management (preferably palliative care team)
- Informed consent from the patient (if competent) or surrogate decision-maker
- Documentation of the refractoriness assessment, consent process, and ethical rationale
- Clear goals: intermittent vs. continuous sedation; level of sedation (proportional to need)
- Discussion of artificial nutrition and hydration, ongoing disease-directed therapy, and resuscitation status
- Multidisciplinary team agreement when feasible
Pharmacological Protocols
Proportional Palliative Sedation (Preferred Approach)
Start with the lowest effective dose to achieve comfort; titrate to effect. The goal is the minimum level of sedation necessary to relieve the refractory symptom.
| Agent | Starting Dose | Titration | Maximum Dose Range | Route |
|---|---|---|---|---|
| Midazolam | 0.5–1 mg IV/SC bolus; then 0.5–1 mg/hr continuous infusion | Increase by 0.5–1 mg/hr every 1–4 hours as needed | Up to 20 mg/hr (rarely higher) | IV, SC |
| Propofol | 10–20 mg IV bolus; then 10–20 mg/hr continuous infusion | Increase by 10 mg/hr every 10–30 minutes as needed | Up to 200 mg/hr (monitor for propofol infusion syndrome at high doses or prolonged use) | IV only |
| Phenobarbital | 100–200 mg IV/SC loading; then 50–100 mg SC/IV every 6–8 hours or continuous infusion at 25–50 mg/hr | Titrate to achieve comfort | Variable; individualized | IV, SC, rectal |
| Levomepromazine (methotrimeprazine) | 12.5–25 mg SC/IV every 6–8 hours | Increase by 12.5–25 mg/dose as needed | Variable | SC, IV (where available) |
Important: Opioids should NOT be used as the primary agent for palliative sedation. However, opioids already in use for pain should be continued (do not withdraw opioids as this will cause pain and withdrawal). The sedative agent is added to the existing opioid regimen.
Monitoring During Palliative Sedation
- Level of sedation (Richmond Agitation-Sedation Scale or Ramsay Sedation Scale)
- Comfort assessment (facial expression, body movements, vocalization) — use behavioral tools such as FLACC
- Respiratory rate and pattern (note: respiratory depression from sedatives is a known risk; in the context of end-of-life care, the goal is comfort, and titration is to comfort rather than to respiratory parameters)
- Family support and communication throughout the process
Survivorship Pain Management
Scope of the Problem
The growing population of cancer survivors faces a significant burden of chronic pain. Estimates indicate that 30–60% of cancer survivors report chronic pain, with approximately 5–10% experiencing severe, disabling chronic pain that persists long after completion of treatment. Survivorship pain may result from the cancer itself (even after cure), cancer treatment, pre-existing pain conditions exacerbated by cancer and treatment, or new pain conditions arising after treatment.7
Common Survivorship Pain Syndromes
| Syndrome | Cancer/Treatment Association | Pain Mechanism | Typical Presentation |
|---|---|---|---|
| Post-mastectomy pain syndrome | Breast cancer surgery | Neuropathic (intercostobrachial nerve injury) | Burning, shooting pain in chest wall, axilla, medial upper arm; allodynia; may persist for years |
| Post-thoracotomy pain syndrome | Lung cancer surgery | Neuropathic (intercostal nerve injury) | Chest wall pain along incision/thoracotomy site; exacerbated by movement, coughing |
| Phantom limb pain | Limb amputation (sarcoma, melanoma) | Neuropathic (central reorganization, peripheral nerve injury) | Pain perceived in the amputated limb; burning, cramping, shooting; may be triggered by emotional stress, weather |
| CIPN (chronic) | Taxane, platinum, vinca alkaloid, bortezomib, thalidomide therapy | Neuropathic (axonal damage) | Numbness, tingling, burning pain in stocking-glove distribution; may persist for months to years |
| Aromatase inhibitor-induced musculoskeletal syndrome | Breast cancer endocrine therapy (AIs) | Arthralgias, myalgias; inflammatory mechanism suspected | Joint pain and stiffness, especially hands, wrists, knees; morning stiffness; can limit adherence to AI therapy |
| Radiation fibrosis syndrome | Post-radiation therapy | Mixed (fibrotic, neuropathic, ischemic) | Progressive fibrosis, pain, weakness in irradiated field; plexopathy; trismus; lymphedema |
| Chronic graft-vs-host disease pain | Allogeneic stem cell transplant | Mixed (inflammatory, neuropathic, musculoskeletal) | Joint contractures, skin pain, oral pain, fascial involvement |
| Post-surgical adhesion pain | Abdominal/pelvic cancer surgery | Visceral, somatic | Chronic abdominal or pelvic pain; may cause bowel obstruction |
| Chronic pelvic pain | Cervical, rectal, prostate cancer treatment (surgery, radiation) | Mixed (neuropathic, fibrotic, visceral) | Pelvic pain, dyspareunia, bladder/bowel symptoms |
Approach to Survivorship Pain Management
Assessment
- Thorough pain assessment (OPQRSTUV framework as described in Part 1)
- Differentiate: recurrent cancer pain vs. treatment-related pain vs. new pain condition
- Imaging and evaluation as indicated to rule out disease recurrence
- Screen for comorbid depression, anxiety, PTSD, fear of recurrence
- Functional assessment: impact on work, relationships, activities
Pharmacological Management
| Principle | Recommendation |
|---|---|
| Non-opioid first approach | For chronic survivorship pain, non-opioid pharmacological agents (adjuvant analgesics, NSAIDs, acetaminophen) are the foundation of treatment |
| Adjuvant analgesics for neuropathic pain | Duloxetine (first-line for CIPN), gabapentin/pregabalin, TCAs — dosed as in Part 4 |
| Anti-inflammatory management | NSAIDs (with GI protection) for musculoskeletal pain including aromatase inhibitor-induced arthralgia; topical NSAIDs for localized joint pain |
| Opioid role in survivorship | Opioids should be reserved for pain not adequately managed by non-opioid strategies; use the lowest effective dose; establish clear functional goals; reassess regularly; use structured monitoring in patients with SUD risk factors |
| Aromatase inhibitor arthralgia | Switching to a different AI may help; duloxetine has evidence for benefit; exercise; acupuncture; consideration of alternative endocrine strategy if pain threatens adherence |
| Topical agents | Lidocaine 5% patches for localized neuropathic pain; topical NSAIDs for joint pain; capsaicin 8% patch for CIPN |
Non-Pharmacological Management (Emphasized in Survivorship)
Non-pharmacological approaches take on particular importance in the survivorship phase, where the goal shifts from acute symptom management to long-term function and quality of life:
- Exercise programs: Regular physical activity is one of the most evidence-supported interventions for cancer survivors with chronic pain; individualized programs including aerobic conditioning, strength training, flexibility, and balance (especially important for CIPN-related imbalance)
- CBT and psychological support: Evidence-based for chronic pain; addresses fear of recurrence, catastrophizing, depression, and activity avoidance
- Physical therapy and rehabilitation: Targeted rehabilitation for specific deficits (e.g., lymphedema therapy, shoulder rehabilitation post-mastectomy, balance training for CIPN)
- Acupuncture: Evidence for aromatase inhibitor arthralgia and CIPN; increasingly recommended in survivorship guidelines
- Vocational rehabilitation: For survivors whose pain affects return to work
- Self-management education: Pain neuroscience education, coping strategies, activity pacing
Opioid De-escalation in Survivors
For cancer survivors who were placed on opioid therapy during active treatment, ongoing need should be reassessed regularly:
- As active cancer treatment concludes and pain sources resolve, initiate a gradual opioid taper
- Optimize non-opioid analgesics and adjuvants before and during taper
- Reduce total daily dose by 10–25% every 1–4 weeks (slower taper for prolonged opioid use)
- Monitor for withdrawal symptoms and pain recurrence
- Involve pain management or addiction medicine if tapering is difficult or if SUD concerns arise
- Some survivors with persistent, well-characterized pain sources may appropriately remain on long-term opioid therapy with structured monitoring (periodic reassessment, functional goals, urine drug testing, PDMP checks)
Principles of Cancer Pain Management Across the Disease Trajectory
| Phase | Pain Management Priorities | Key Considerations |
|---|---|---|
| Diagnosis / Early Treatment | Aggressive assessment; rapid pain control; minimize interference with anticancer treatment | Pain may be the presenting symptom; imaging correlation essential; do not delay pain treatment pending definitive diagnosis |
| Active Anticancer Treatment | Ongoing pain management alongside chemotherapy, radiation, surgery; manage treatment-related pain | CIPN monitoring; mucositis management; pre-emptive analgesia for procedures; drug interactions between analgesics and anticancer agents |
| Stable Disease / Remission | Optimize long-term regimen; minimize opioid side effects; enhance function | Consider opioid rotation if side effects problematic; step down analgesics as able; address psychosocial needs |
| Progressive Disease | Escalate as needed; early palliative care integration; interventional approaches; address total pain (physical, psychological, social, spiritual) | Anticipate increasing pain with disease progression; do not delay dose escalation; address goals of care |
| End of Life | Comfort as the primary goal; simplify regimen (reduce unnecessary medications); prepare for refractory symptoms | Switch to parenteral or transdermal routes if unable to swallow; prepare for possible need for palliative sedation; support family |
| Survivorship | Chronic pain management; non-opioid emphasis; functional rehabilitation; psychosocial support | De-escalate opioids when appropriate; address CIPN; survivorship care plans; long-term monitoring |
Summary of Key Recommendations
Screen for pain at every encounter using validated tools appropriate to the patient’s age, cognitive status, and communication ability.
Perform a comprehensive pain assessment (OPQRSTUV framework) for all patients with clinically significant pain, identifying pain mechanism(s) to guide treatment selection.
Apply the analgesic ladder with modern modifications: non-opioid analgesics for mild pain; strong opioids (or weak opioids) with or without non-opioids for moderate-to-severe pain; adjuvant analgesics based on pain mechanism at every step.
Individualize opioid therapy: select opioids based on patient comorbidities, organ function, and prior response; start at appropriate doses in opioid-naive patients; titrate based on pain response and tolerability; prescribe around-the-clock dosing with breakthrough medication.
Use equianalgesic dosing tables as starting points for opioid conversions, always applying a 25–50% dose reduction for incomplete cross-tolerance; methadone requires special conversion protocols.
Proactively manage opioid side effects: prescribe a bowel regimen with every opioid prescription; anticipate and treat nausea, sedation, and other adverse effects; consider opioid rotation for refractory side effects.
Add adjuvant analgesics for neuropathic pain (gabapentin, pregabalin, duloxetine, TCAs), bone pain (NSAIDs, corticosteroids, bisphosphonates, denosumab), and pain with inflammatory or compressive components (corticosteroids).
Consider interventional approaches early for amenable pain syndromes (celiac plexus block for pancreatic cancer pain, palliative radiation for bone metastases, vertebroplasty for vertebral compression fractures, neuraxial drug delivery for refractory pain).
Duloxetine is the first-line pharmacological treatment for CIPN; no agent has strong evidence for CIPN prevention; dose modification of the causative agent remains the primary preventive strategy.
Integrate non-pharmacological approaches including CBT, physical therapy, exercise, and complementary therapies (acupuncture, massage) into the comprehensive pain management plan.
Address special populations with tailored approaches: reduced doses and careful selection in elderly and organ-impaired patients; structured opioid prescribing in patients with SUD history; age-appropriate assessment and weight-based dosing in pediatric patients.
Palliative sedation is an ethically appropriate intervention of last resort for truly refractory symptoms at end of life, requiring informed consent, careful documentation, and proportional dosing.
Survivorship pain management emphasizes non-opioid strategies, functional rehabilitation, psychological support, and structured opioid de-escalation.
References
Paice JA, Portenoy R, Lacchetti C, et al. “Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.” Journal of Clinical Oncology, 34(27): 3325–3345, 2016. Updated 2024. American Society of Clinical Oncology (ASCO). DOI: 10.1200/JCO.2016.68.5206 ↩︎
World Health Organization. “WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses.” Geneva: World Health Organization, 2012. ISBN: 978-92-4-154812-0 ↩︎
King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. “A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.” Palliative Medicine, 25(5): 525–552, 2011. DOI: 10.1177/0269216311406313 ↩︎
Pergolizzi JV Jr, Gharibo C, Engeler D, et al. “Management of cancer pain with substance use disorder: an expert panel opinion.” Journal of Clinical Medicine, 10(19): 4540, 2021. DOI: 10.3390/jcm10194540 ↩︎
Paice JA, Portenoy R, Lacchetti C, et al. “Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.” Journal of Clinical Oncology, 34(27): 3325–3345, 2016. Updated 2024. American Society of Clinical Oncology (ASCO). ↩︎
Cherny NI, Radbruch L, Board of the European Association for Palliative Care. “European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care.” Palliative Medicine, 23(7): 581–593, 2009. DOI: 10.1177/0269216309107024 ↩︎
Leysen L, Beckwée D, Nijs J, et al. “Risk factors of pain in breast cancer survivors: a systematic review and meta-analysis.” Supportive Care in Cancer, 25(12): 3607–3643, 2017. DOI: 10.1007/s00520-017-3824-3 ↩︎